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Viable: Yes, No, or Somewhere in the Middle?*
George A. Beller, MD, Loren P. Budge, MD
Charlottesville, VirginiaViability testing plays a key role in the treatment of
patients with ischemic cardiomyopathy. We have
long known that, for patients with coronary artery
disease, having decreased left ventricular function
carries an increased risk of mortality, hospital stay,
arrhythmia, and decreased quality of life. Revascu-
larizing these individuals also poses significant risk.
It is clear that many patients do not benefit and
might even be harmed by inappropriate interven-
tion. There is a strong association between the
amount of viable myocardium, measured with a
See page 1060
variety of noninvasive testing modalities, and the
likelihood of improvement in heart failure symp-
toms, exercise capacity, event rates, and overall
mortality after revascularization (1–3). Until re-
cently, the data for viability were predominately
observational. The PARR-2 (PET and Recovery
Following Revascularization-2) study by Beanlands
et al. (4) was the first randomized controlled trial to
prospectively evaluate whether therapy guided by
positron emission tomography with F-18 labeled
fluorodeoxyglucose (PET-FDG) could improve car-
diovascular outcomes in patients with decreased left
ventricular function being considered for revascular-
ization. This study failed to show a statistically signif-
icant difference in the primary composite end point of
cardiac death, myocardial infarction (MI), or repeat
cardiac hospital stay at 1 year. An important contrib-
uting factor was that treating physicians in the study
were not bound to follow the PET-FDG–generated
guidance regarding whether or not to proceed with
revascularization and in fact went against viability-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Division of Cardiovascular Medicine, University of Virginia
Health System, Charlottesville, Virginia.based recommendations a full 25% of the time. The
authors concluded that if “patients [and their phy-
sicians] adhere to FDG PET recommendations, a
reduction in events might be realized.”
In this issue of iJACC, D’Egidio et al. (5) present
a post hoc substudy of the PARR-2 trial, looking
only at those patients in the parent trial who
underwent PET-FDG imaging. They found that
increasing amounts of perfusion-metabolism mis-
match correlated significantly with increasing ben-
efit from revascularization. Although the composite
outcome was driven in large measure by repeat
hospital stays for angina and was not powered to
look at individual end points such as death or MI,
this study does support a growing body of evidence
that viability testing is a powerful predictor of
cardiovascular outcome after revascularization. The
authors in this study also found that worsened
kidney function significantly and independently
predicted poorer outcomes after revascularization.
One of the contributions of this report is that it
illustrates that viability can (and probably should)
be viewed as a continuous rather than dichotomous
variable. All of the leading imaging modalities used
to assess viability (PET-FDG, single-photon
emission computed tomography, and cardiac mag-
netic resonance [CMR]) are able to fairly easily
identify viability or the lack thereof at either end of
the spectrum. Patients with either clear-cut viability
or transmural infarction fairly reliably respond to
revascularization as their viability scores would pre-
dict, independent of ejection fraction (6). But each
modality also has a grey zone where the presence or
absence of viability is more difficult to determine
and is often decided by a somewhat arbitrary cut
point. These cut points are usually statistically
derived and lie in the middle of a continuum rather
than falling on a natural step-up or step-down of
outcomes (7). The treating physicians in the
PARR-2 trial who did not follow the PET-FDG–
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1070uided recommendations for revascularization most
ften did so in this middle zone of “moderate
iability.” What should we do when a patient is in
his middle ground? Although viability cut points
re necessary for research applications, their clinical
enefit is probably more modest. Even if the 7%
utoff found in this trial is validated in future
tudies, it might not be correct to assume that
omeone with mismatch close to the cut point will
espond in the same way as someone at the far end
f the spectrum. It is also difficult to know how to
pply cut points to individual patients, many of
hom do not reliably respond as their mid-range
iability score would predict. Perhaps we need to
ecognize that the question of viability might not
lways have a black or white answer. When patients
re in this grey zone, other factors affecting their
utcome also need to be considered.
Some important factors that need to be taken
nto account along with a patient’s viability results
re kidney function, mitral regurgitation, left ven-
ricular end-diastolic volume, and the presence of
ngina. Poor kidney function has repeatedly been
hown to be one of the most potent independent
isk factors for mortality after coronary artery bypass
rafting (CABG) (8), a finding that was confirmed
n the present study (5). The risk of death after
evascularization increases incrementally as kidney
unction worsens (9) and should increase our
hreshold for intervention accordingly. Adding mi-
ral valve repair or replacement (MVR) to CABG
lso significantly increases the risk of short- and
ong-term mortality. Absence of viability in the
resence of severe mitral regurgitation portends a
oor prognosis after revascularization. It has been
hown, however, that the presence of viability is a
articularly strong predictor of survival in patients
ith significant ischemic mitral regurgitation re-
erred for surgical revascularization with consider-
tion of MVR (10,11). Therefore, in this subgroup
f patients it might be especially useful to heed the
esults of viability testing. Another independent
redictor of mortality was demonstrated by Santana
t al. (12), who showed that increased end-diastolic
olume (260 ml) and elevated end-systolic vol-
mes (200 ml) portended poorer event-free sur-
ival 2 years after revascularization, independent of
ET-FDG mismatch, revealing that a remodeled
eft ventricle—even in the absence of scar—is less
ikely to regain function after revascularization.
inally, patients’ symptoms should also affect our
hreshold for intervention. A patient with low-
oderate viability but persistent angina despite oedical therapy might be a more reasonable candi-
ate for intervention than an asymptomatic patient
ith a viability score just above the cut point. These
nd other comorbidities proven to affect revascular-
zation outcomes should inform our decision of
hether or not to intervene, especially when viabil-
ty testing is in the moderate range.
Two valuable imaging modalities used to assess
iability include PET-FDG and CMR imaging.
ET-FDG offers excellent sensitivity due to its
bility to image both perfusion and the metabolic
erangements found in ischemic myocardium. Re-
orted positive and negative predictive values and
iagnostic accuracy for PET-FDG in predicting
unctional recovery after revascularization are 86%,
00%, and 90%, respectively (13). In contrast, the
patial and temporal resolution of CMRmake it the
old standard for assessing left ventricular function
nd volumes as well as the presence, size, and
ransmural extent of scar formation and microvas-
ular obstruction. It has been shown that the
ransmurality of an infarct seen on delayed gadolin-
um enhanced images accurately predicts long-term
emodeling and improvement in left ventricular
unction after revascularization (14), with the pres-
nce of microvascular obstruction adding additional
rognostic value (15). Accuracy is further improved
ith CMR assessment of functional recovery with
ow-dose dobutamine, especially in areas of non-
ransmural infarction (16). Current data suggest
hat PET-FDG is probably more sensitive and
MR more specific in defining areas of myocar-
ium that are likely to improve with revasculariza-
ion (13,17). Ongoing improvement of imaging
rotocols and the development of hybrid imaging
odalities such as PET-CMR might serve to
educe the size of the grey zone and improve our
bility to predict who will respond well to invasive
herapies.
Ongoing studies that will shed further light on
his subject include the STICH (Surgical Treat-
ent for Ischemic Heart Failure) trial (18), which
as randomized over 1,200 patients with severely
ecreased left ventricular function to either medical
anagement or bypass surgery, many of whom had
iability testing with CMR performed as part of
heir initial evaluation. Future randomized studies
imilar to PARR-2 but that take into account
hysician and patient discretion in cases of mod-
rate viability are needed to conclusively demon-
trate that viability testing can lead to improved
utcomes.
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1071In summary, viability testing is an extremely
seful tool for predicting outcomes after revascular-
zation in patients with ischemic cardiomyopathy.
atients who are in the mid-range of viability will
ikely benefit from a thoughtful approach taking
nto account kidney function, symptoms, and other
omorbidities to obtain the best possible outcome.nance versus SPECT: are all nonin- Recovery of left venill likely serve to narrow the grey zone and allow
or even more accurate predictions of who will
enefit from revascularization.
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